RE-MEDY Cumulative Risk Recurrent Venous Thromboembolism or Related Death in the Active-Control Study Months since Randomization Estimated Cumulative Risk (%) Dabigatran Warfarin P=0.01 for noninferiority Schulman S. N Engl J Med 2013;368:

RE-SONATE Cumulative Risk Recurrent Venous Thromboembolism, Related Death, or Unexplained Death in the Placebo- Control Study Schulman S. N Engl J Med 2013;368: Estimated Cumulative Risk (%) Months since Randomization Post-Treatment Follow-up Treatment Phase Dabigatran Matching placebo P=0.01 at 6 mo P=0.006 at 12 mo P=0.03 at 18 mo

RE-MEDY Any Bleeding in the Active-Control Study Months since First Dose of Study Drug Estimated Cumulative Risk of Bleeding (%) Schulman S. N Engl J Med 2013;368: Dabigatran Warfarin P<0.001

RE-SONATE Any Bleeding in the Placebo-Control Study Months since First Dose of Study Drug Estimated Cumulative Risk of Bleeding (%) Schulman S. N Engl J Med 2013;368: Dabigatran Matching placebo P=0.003